- For treatment of postmenopausal osteoporosis, a single 5 mg infusion once a year is recommended.
- For prevention of postmenopausal osteoporosis the recommended dose is 5 mg every two years.
- Paget's disease of bone is treated with a single 5 mg infusion. Patients with Paget's disease should also receive 1500 mg of elemental calcium and 800 IU vitamin D daily, especially during the two weeks after the injection of Reclast.
- For prevention or treatment of steroid-induced osteoporosis, the recommended dose is 5 mg once yearly.
- Combining Reclast with aminoglycoside antibiotics such as gentamycin or loop diuretics such as furosemide (Lasix) or bumetanide (Bumex) may lead to reduced calcium in blood.
- Reclast should be used with caution in patients who are taking drugs that affect kidney function because Reclast has been associated with reduced kidney function.
- Since Reclast contains the same active ingredient as zoledronic acid (Zometa), patients treated with Zometa should not receive Reclast.
PREGNANCY AND BREASTFEEDING SAFETY:
- Reclast should not be administered to pregnant women. Women of childbearing age should be advised to use a reliable method of birth control.
- It is not known whether Reclast is excreted in human milk. Since many drugs are excreted in human milk, and Reclast binds to bone long-term, Reclast should not be administered to nursing women.
PREPARATIONS: Solution: 5 mg/100 ml
- Unopened bottles should be kept at room temperature 15 C-30 C (59 F-86 F).
- Opened bottles of solution are stable for 24 hours at 2 C-8 C (36 F-46 F).
Quick GuideWhat Is Osteoporosis? Treatment, Symptoms, Medication
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.